{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:25:19Z","timestamp":1775121919344,"version":"3.50.1"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40273-025-01504-0","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T07:32:38Z","timestamp":1747985558000},"page":"1001-1045","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children\u2014Targeted Literature Reviews"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1960-4552","authenticated-orcid":false,"given":"Min","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5937-0936","authenticated-orcid":false,"given":"Jipan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5219-2612","authenticated-orcid":false,"given":"Hela","family":"Romdhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-2813","authenticated-orcid":false,"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5281-2463","authenticated-orcid":false,"given":"Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-8036","authenticated-orcid":false,"given":"Elamin","family":"Elbasha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-6467","authenticated-orcid":false,"given":"Salini","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Rowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8819-2315","authenticated-orcid":false,"given":"Matthew S.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"1504_CR1","doi-asserted-by":"crossref","unstructured":"Feldman C, Anderson R. Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections. F1000Res. 2020;9:F1000 Faculty Rev-338.","DOI":"10.12688\/f1000research.22341.1"},{"issue":"7","key":"1504_CR2","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","volume":"6","author":"B Wahl","year":"2018","unstructured":"Wahl B, O\u2019Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000\u201315. Lancet Glob Health. 2018;6(7):e744\u201357.","journal-title":"Lancet Glob Health"},{"key":"1504_CR3","unstructured":"Gierke RW,Wodi AP, Kobayashi, M. Pneumococcal Disease. 2021. Available from: https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/downloads\/pneumo.pdf. Accessed 27 Feb 2023."},{"issue":"5","key":"1504_CR4","doi-asserted-by":"publisher","first-page":"2082205","DOI":"10.1080\/21645515.2022.2082205","volume":"18","author":"D Amicizia","year":"2022","unstructured":"Amicizia D, Astengo M, Paganino C, Piazza MF, Sticchi C, Orsi A, et al. Economic burden of pneumococcal disease in children in Liguria, Italy. Hum Vaccin Immunother. 2022;18(5):2082205.","journal-title":"Hum Vaccin Immunother"},{"key":"1504_CR5","doi-asserted-by":"crossref","unstructured":"Barbieri E, Porcu G, Petigara T, Senese F, Prandi GM, Scamarcia A, et al. The economic burden of pneumococcal disease in children: a population-based investigation in the Veneto Region of Italy. Children (Basel). 2022;9(9):1347.","DOI":"10.3390\/children9091347"},{"issue":"3","key":"1504_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/03007995.2021.1876007","volume":"37","author":"J Darb\u00e0","year":"2021","unstructured":"Darb\u00e0 J, Mars\u00e0 A. Hospital incidence, in-hospital mortality and medical costs of pneumococcal disease in Spain (2008\u20132017): a retrospective multicentre study. Curr Med Res Opin. 2021;37(3):523\u201330.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1504_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12913-023-09244-7","volume":"23","author":"T Hu","year":"2023","unstructured":"Hu T, Song Y, Done N, Mohanty S, Liu Q, Sarpong EM, et al. Economic burden of acute otitis media, pneumonia, and invasive pneumococcal disease in children in the United States after the introduction of 13-valent pneumococcal conjugate vaccines during 2014\u20132018. BMC Health Serv Res. 2023;23(1):398.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"1504_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40121-020-00294-6","volume":"9","author":"MR Wilson","year":"2020","unstructured":"Wilson MR, Wasserman MD, Breton MC, Peloquin F, Earnshaw SR, McDade C, et al. Health and economic impact of routine pediatric pneumococcal immunization programs in Canada: a retrospective analysis. Infect Dis Ther. 2020;9(2):341\u201353.","journal-title":"Infect Dis Ther"},{"issue":"4","key":"1504_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.idc.2015.07.009","volume":"29","author":"I Yildirim","year":"2015","unstructured":"Yildirim I, Shea KM, Pelton SI. Pneumococcal disease in the era of pneumococcal conjugate vaccine. Infect Dis Clin North Am. 2015;29(4):679\u201397.","journal-title":"Infect Dis Clin North Am"},{"issue":"5","key":"1504_CR10","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/microorganisms9050900","volume":"9","author":"N Schiess","year":"2021","unstructured":"Schiess N, Groce NE, Dua T. The impact and burden of neurological sequelae following bacterial meningitis: a narrative review. Microorganisms. 2021;9(5):900.","journal-title":"Microorganisms."},{"key":"1504_CR11","unstructured":"WHO. Meningitis. 2023. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/meningitis. Accessed 7 Apr 2024."},{"issue":"2","key":"1504_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jinf.2010.04.008","volume":"61","author":"M Jit","year":"2010","unstructured":"Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J Infect. 2010;61(2):114\u201324.","journal-title":"J Infect"},{"key":"1504_CR13","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-0181","author":"R Kaur","year":"2017","unstructured":"Kaur R, Morris M, Pichichero ME. Epidemiology of acute otitis media in the postpneumococcal conjugate vaccine era. Pediatrics. 2017.","journal-title":"Pediatrics"},{"issue":"3","key":"1504_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1128\/CMR.00018-12","volume":"25","author":"TQ Tan","year":"2012","unstructured":"Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev. 2012;25(3):409\u201319.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"1504_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11136-021-02941-y","volume":"31","author":"R O'Reilly","year":"2022","unstructured":"O\u2019Reilly R, Yokoyama S, Boyle J, Kwong JC, McGeer A, To T, et al. The impact of acute pneumococcal disease on health state utility values: a systematic review. Qual Life Res. 2022;31(2):375\u201388.","journal-title":"Qual Life Res"},{"key":"1504_CR16","unstructured":"Food and Drug Administration. Label for 15-valent pneumococcal conjugate vaccine. Available from: https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/1158fa93-ef41-4a29-8252-9251f94c53c8\/spl-doc?hl=Pneumococcal%2015-valent%20Conjugate%20Vaccine. Accessed 07 Apr 2024."},{"key":"1504_CR17","unstructured":"Food and Drug Administration. Label for 20-valent pneumococcal conjugate vaccine. Available from: https:\/\/www.fda.gov\/media\/149987\/download. Accessed 07 Apr 2024."},{"key":"1504_CR18","unstructured":"European Medicines Agency. Label for pneumococcal 15-valent conjugate vaccine. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxneuvance. Accessed 7 Apr 2024."},{"key":"1504_CR19","unstructured":"European Medicines Agency. Label for pneumococcal 20-valent conjugate vaccine. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/prevenar-20-previously-apexxnar. Accessed 7 Apr 2024."},{"issue":"11","key":"1504_CR20","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jval.2019.06.011","volume":"22","author":"T Shiri","year":"2019","unstructured":"Shiri T, Khan K, Keaney K, Mukherjee G, McCarthy ND, Petrou S. Pneumococcal disease: a systematic review of health utilities, resource use, costs, and economic evaluations of interventions. Value Health. 2019;22(11):1329\u201344.","journal-title":"Value Health."},{"issue":"4","key":"1504_CR21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jval.2022.10.006","volume":"26","author":"MS Syeed","year":"2023","unstructured":"Syeed MS, Ghule P, Le LM, Veettil SK, Horn EK, Perdrizet J, et al. Pneumococcal vaccination in children: a systematic review and meta-analysis of cost-effectiveness studies. Value Health. 2023;26(4):598\u2013611.","journal-title":"Value Health."},{"key":"1504_CR22","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. NICE process and methods [PMG36]. 31 October 2023; Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741. Accessed 14 May 2024."},{"issue":"2","key":"1504_CR23","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1093\/pubmed\/fdab159","volume":"44","author":"Z Tang","year":"2022","unstructured":"Tang Z, Matanock A, Jeon S, Leidner AJ. A review of health-related quality of life associated with pneumococcal disease: pooled estimates by age and type of disease. J Public Health (Oxf). 2022;44(2):e234\u201340.","journal-title":"J Public Health (Oxf)"},{"key":"1504_CR24","unstructured":"Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. 2009. Available from: https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf. Accessed 24 Aug 2023."},{"key":"1504_CR25","doi-asserted-by":"crossref","unstructured":"Ansaldi F, Pugh S, Amicizia D, Di Virgilio R, Trucchi C, Orsi A, et al. Estimating the clinical and economic impact of switching from the 13-valent pneumococcal conjugate vaccine (PCV13) to the 10-valent pneumococcal conjugate vaccine (PCV10) in Italy. Pathogens. 2020;9(2).","DOI":"10.3390\/pathogens9020076"},{"key":"1504_CR26","doi-asserted-by":"crossref","unstructured":"Beutels P, Blommaert A, Hanquet G, Bilcke J, Thiry N, Sabbe M, et al. Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood. 2011.","DOI":"10.57598\/R155C"},{"issue":"28","key":"1504_CR27","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1016\/j.vaccine.2012.04.028","volume":"30","author":"PR Blank","year":"2012","unstructured":"Blank PR, Szucs TD. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland. Vaccine. 2012;30(28):4267\u201375.","journal-title":"Vaccine"},{"issue":"10","key":"1504_CR28","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1016\/S0149-2918(03)80322-3","volume":"25","author":"JM Bos","year":"2003","unstructured":"Bos JM, R\u00fcmke H, Welte R, Postma MJ. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther. 2003;25(10):2614\u201330.","journal-title":"Clin Ther"},{"issue":"1","key":"1504_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clinthera.2011.12.007","volume":"34","author":"A By","year":"2012","unstructured":"By A, Sobocki P, Forsgren A, Silfverdal SA. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model. Clin Ther. 2012;34(1):177\u201389.","journal-title":"Clin Ther"},{"issue":"10","key":"1504_CR30","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1080\/21645515.2017.1343773","volume":"13","author":"P Castiglia","year":"2017","unstructured":"Castiglia P, Pradelli L, Castagna S, Freguglia V, Pal\u00f9 G, Esposito S. Overall effectiveness of pneumococcal conjugate vaccines: an economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy. Hum Vaccin Immunother. 2017;13(10):2307\u201315.","journal-title":"Hum Vaccin Immunother"},{"issue":"33","key":"1504_CR31","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1016\/j.vaccine.2010.05.058","volume":"28","author":"AW Chuck","year":"2010","unstructured":"Chuck AW, Jacobs P, Tyrrell G, Kellner JD. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine. 2010;28(33):5485\u201390.","journal-title":"Vaccine"},{"issue":"1","key":"1504_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10198-008-0098-1","volume":"10","author":"C Claes","year":"2009","unstructured":"Claes C, Reinert RR, von der Schulenburg JM. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur J Health Econ. 2009;10(1):25\u201338.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1504_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.provac.2009.07.012","volume":"1","author":"P De Wals","year":"2009","unstructured":"De Wals P, Poirier B, Petit G, Erickson L, P\u00e9pin J. Simulation model for comparing the costs and effectiveness of different pneumococcal conjugate vaccines. Procedia Vaccinol. 2009;1(1):67\u201372.","journal-title":"Procedia Vaccinol."},{"issue":"11","key":"1504_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010776","volume":"6","author":"E Delgleize","year":"2016","unstructured":"Delgleize E, Leeuwenkamp O, Theodorou E, Van de Velde N. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model. BMJ Open. 2016;6(11): e010776.","journal-title":"BMJ Open"},{"issue":"52","key":"1504_CR35","doi-asserted-by":"publisher","first-page":"9640","DOI":"10.1016\/j.vaccine.2011.10.038","volume":"29","author":"J D\u00edez-Domingo","year":"2011","unstructured":"D\u00edez-Domingo J, Ridao-L\u00f3pez M, Guti\u00e9rrez-Gimeno MV, Puig-Barber\u00e1 J, Lluch-Rodrigo JA, Pastor-Villalba E. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain). Vaccine. 2011;29(52):9640\u20138.","journal-title":"Vaccine"},{"issue":"1","key":"1504_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1471-2334-12-101","volume":"12","author":"SR Earnshaw","year":"2012","unstructured":"Earnshaw SR, McDade CL, Zanotti G, Farkouh RA, Strutton D. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect Dis. 2012;12(1):101.","journal-title":"BMC Infect Dis"},{"issue":"23","key":"1504_CR37","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1016\/S0264-410X(03)00193-2","volume":"21","author":"SM Ess","year":"2003","unstructured":"Ess SM, Schaad UB, Gervaix A, Pin\u00f6sch S, Szucs TD. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine. 2003;21(23):3273\u201381.","journal-title":"Vaccine"},{"key":"1504_CR38","doi-asserted-by":"crossref","unstructured":"Huang M, Hu T, Weaver J, Owusu-Edusei K, Elbasha E. Cost-effectiveness analysis of routine use of 15-valent pneumococcal conjugate vaccine in the US pediatric population. Vaccines (Basel). 2023;11(1):135.","DOI":"10.3390\/vaccines11010135"},{"issue":"18","key":"1504_CR39","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1016\/j.vaccine.2007.01.088","volume":"25","author":"GA Hubben","year":"2007","unstructured":"Hubben GA, Bos JM, Glynn DM, van der Ende A, van Alphen L, Postma MJ. Enhanced decision support for policy makers using a web interface to health-economic models\u2014illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine. 2007;25(18):3669\u201378.","journal-title":"Vaccine"},{"issue":"2","key":"1504_CR40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.clinthera.2012.12.006","volume":"35","author":"RM Klok","year":"2013","unstructured":"Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Clin Ther. 2013;35(2):119\u201334.","journal-title":"Clin Ther"},{"issue":"1","key":"1504_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3111\/13696998.2011.622323","volume":"15","author":"G Knerer","year":"2012","unstructured":"Knerer G, Ismaila A, Pearce D. Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise. J Med Econ. 2012;15(1):61\u201376.","journal-title":"J Med Econ"},{"issue":"3","key":"1504_CR42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10198-016-0770-9","volume":"18","author":"A Kuhlmann","year":"2017","unstructured":"Kuhlmann A, von der Schulenburg JG. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. Eur J Health Econ. 2017;18(3):273\u201392.","journal-title":"Eur J Health Econ"},{"issue":"2","key":"1504_CR43","doi-asserted-by":"publisher","first-page":"2257426","DOI":"10.1080\/21645515.2023.2257426","volume":"19","author":"D Lytle","year":"2023","unstructured":"Lytle D, Grajales Beltr\u00e1n AG, Perdrizet J, Ait Yahia N, Cane A, Yarnoff B, et al. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population. Hum Vaccin Immunother. 2023;19(2):2257426.","journal-title":"Hum Vaccin Immunother"},{"issue":"13","key":"1504_CR44","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/1471-2334-13-229","volume":"21","author":"LJ McGarry","year":"2013","unstructured":"McGarry LJ, Gilmore KE, Rubin JL, Klugman KP, Strutton DR, Weinstein MC. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States. BMC Infect Dis. 2013;13:229.","journal-title":"BMC Infect Dis"},{"issue":"31\u201332","key":"1504_CR45","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1016\/j.vaccine.2004.05.003","volume":"22","author":"A Melegaro","year":"2004","unstructured":"Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31\u201332):4203\u201314.","journal-title":"Vaccine"},{"issue":"50","key":"1504_CR46","doi-asserted-by":"publisher","first-page":"7105","DOI":"10.1016\/j.vaccine.2009.09.057","volume":"27","author":"B Poirier","year":"2009","unstructured":"Poirier B, De Wals P, Petit G, Erickson LJ, P\u00e9pin J. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine. 2009;27(50):7105\u20139.","journal-title":"Vaccine"},{"issue":"18","key":"1504_CR47","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1016\/j.vaccine.2023.03.045","volume":"41","author":"N Prasad","year":"2023","unstructured":"Prasad N, Stoecker C, Xing W, Cho BH, Leidner AJ, Kobayashi M. Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States. Vaccine. 2023;41(18):2914\u201321.","journal-title":"Vaccine"},{"issue":"2","key":"1504_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40121-020-00287-5","volume":"9","author":"S Pugh","year":"2020","unstructured":"Pugh S, Wasserman M, Moffatt M, Marques S, Reyes JM, Prieto VA, et al. Estimating the impact of switching from a lower to higher valent pneumococcal conjugate vaccine in Colombia, Finland, and the Netherlands: a cost-effectiveness analysis. Infect Dis Ther. 2020;9(2):305\u201324.","journal-title":"Infect Dis Ther"},{"issue":"47","key":"1504_CR49","doi-asserted-by":"publisher","first-page":"8564","DOI":"10.1016\/j.vaccine.2011.09.025","volume":"29","author":"B Robberstad","year":"2011","unstructured":"Robberstad B, Frostad CR, Akselsen PE, Kv\u00e6rner KJ, Berstad AK. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine. 2011;29(47):8564\u201374.","journal-title":"Vaccine"},{"issue":"12","key":"1504_CR50","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.vaccine.2010.01.005","volume":"28","author":"MH Rozenbaum","year":"2010","unstructured":"Rozenbaum MH, Hoek AJ, Hak E, Postma MJ. Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). Vaccine. 2010;28(12):2367\u20139.","journal-title":"Vaccine"},{"issue":"1","key":"1504_CR51","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1080\/13696998.2024.2339638","volume":"27","author":"MH Rozenbaum","year":"2024","unstructured":"Rozenbaum MH, Huang L, Cane A, Arguedas A, Chapman R, Dillon-Murphy D, et al. Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13. J Med Econ. 2024;27(1):644\u201352.","journal-title":"J Med Econ"},{"issue":"3","key":"1504_CR52","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.vaccine.2023.12.057","volume":"42","author":"MH Rozenbaum","year":"2024","unstructured":"Rozenbaum MH, Huang L, Perdrizet J, Cane A, Arguedas A, Hayford K, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants. Vaccine. 2024;42(3):573\u201382.","journal-title":"Vaccine"},{"issue":"340","key":"1504_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2509","volume":"2","author":"MH Rozenbaum","year":"2010","unstructured":"Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;340: c2509.","journal-title":"BMJ"},{"issue":"345","key":"1504_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e6879","volume":"26","author":"MH Rozenbaum","year":"2012","unstructured":"Rozenbaum MH, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ. 2012;26(345): e6879.","journal-title":"BMJ"},{"issue":"10","key":"1504_CR55","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2334-10-14","volume":"21","author":"JL Rubin","year":"2010","unstructured":"Rubin JL, McGarry LJ, Klugman KP, Strutton DR, Gilmore KE, Weinstein MC. Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic. BMC Infect Dis. 2010;10:14.","journal-title":"BMC Infect Dis"},{"issue":"48","key":"1504_CR56","doi-asserted-by":"publisher","first-page":"7634","DOI":"10.1016\/j.vaccine.2010.09.049","volume":"28","author":"JL Rubin","year":"2010","unstructured":"Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28(48):7634\u201343.","journal-title":"Vaccine"},{"issue":"11\u201312","key":"1504_CR57","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/00365540500321512","volume":"37","author":"H Salo","year":"2005","unstructured":"Salo H, Sintonen H, Nuorti JP, Linna M, Nohynek H, Verho J, et al. Economic evaluation of pneumococcal conjugate vaccination in Finland. Scand J Infect Dis. 2005;37(11\u201312):821\u201332.","journal-title":"Scand J Infect Dis"},{"issue":"2","key":"1504_CR58","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1542\/peds.2012-3350","volume":"132","author":"C Stoecker","year":"2013","unstructured":"Stoecker C, Hampton LM, Link-Gelles R, Messonnier ML, Zhou F, Moore MR. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine. Pediatrics. 2013;132(2):e324\u201332.","journal-title":"Pediatrics"},{"issue":"1","key":"1504_CR59","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jinf.2011.10.015","volume":"64","author":"DR Strutton","year":"2012","unstructured":"Strutton DR, Farkouh RA, Earnshaw SR, Hwang S, Theidel U, Kontodimas S, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and the Netherlands. J Infect. 2012;64(1):54\u201367.","journal-title":"J Infect"},{"issue":"6","key":"1504_CR60","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40121-024-00977-4","volume":"13","author":"A Ta","year":"2024","unstructured":"Ta A, K\u00fchne F, Laurenz M, von Eiff C, Warren S, Perdrizet J. Cost-effectiveness of PCV20 to prevent pneumococcal disease in the pediatric population: a German societal perspective analysis. Infect Dis Ther. 2024;13(6):1333\u201358.","journal-title":"Infect Dis Ther"},{"issue":"28 Suppl 6","key":"1504_CR61","doi-asserted-by":"publisher","first-page":"G23","DOI":"10.1016\/j.vaccine.2010.06.016","volume":"19","author":"SE Talbird","year":"2010","unstructured":"Talbird SE, Taylor TN, Knoll S, Frostad CR, Garc\u00eda MS. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine. 2010;19(28 Suppl 6):G23\u20139.","journal-title":"Vaccine"},{"issue":"50","key":"1504_CR62","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1016\/j.vaccine.2012.10.017","volume":"30","author":"AJ van Hoek","year":"2012","unstructured":"van Hoek AJ, Choi YH, Trotter C, Miller E, Jit M. The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine. 2012;30(50):7205\u201313.","journal-title":"Vaccine"},{"issue":"7","key":"1504_CR63","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.4161\/hv.29008","volume":"10","author":"P Vemer","year":"2014","unstructured":"Vemer P, Postma MJ. A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children. Hum Vaccin Immunother. 2014;10(7):1841\u20139.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"1504_CR64","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40121-018-0206-1","volume":"7","author":"M Wilson","year":"2018","unstructured":"Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, et al. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018;7(3):353\u201371.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"1504_CR65","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1542\/peds.2008-1482","volume":"123","author":"MA O'Brien","year":"2009","unstructured":"O\u2019Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, et al. New vaccines against otitis media: projected benefits and cost-effectiveness. Pediatrics. 2009;123(6):1452\u201363.","journal-title":"Pediatrics"},{"issue":"6","key":"1504_CR66","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/01.inf.0000222403.42974.8b","volume":"25","author":"GT Ray","year":"2006","unstructured":"Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J. 2006;25(6):494\u2013501.","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"1504_CR67","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40121-024-00944-z","volume":"13","author":"MH Rozenbaum","year":"2024","unstructured":"Rozenbaum MH, Chilson E, Farkouh R, Huang L, Cane A, Arguedas A, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine among US children with underlying medical conditions. Infect Dis Ther. 2024;13(4):745\u201360.","journal-title":"Infect Dis Ther"},{"issue":"8","key":"1504_CR68","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/vaccines11081369","volume":"11","author":"S Warren","year":"2023","unstructured":"Warren S, Barmpouni M, Kossyvaki V, Gourzoulidis G, Perdrizet J. Estimating the clinical and economic impact of switching from the 13-valent pneumococcal conjugate vaccine (PCV13) to higher-valent options in Greek infants. Vaccines (Basel). 2023;11(8):1369.","journal-title":"Vaccines (Basel)."},{"issue":"7","key":"1504_CR69","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/vaccines11071168","volume":"11","author":"M Wilson","year":"2023","unstructured":"Wilson M, Lucas A, Mendes D, Vyse A, Mikudina B, Czudek C, et al. Estimating the cost-effectiveness of switching to higher-valency pediatric pneumococcal conjugate vaccines in the United Kingdom. Vaccines (Basel). 2023;11(7):1168.","journal-title":"Vaccines (Basel)."},{"issue":"12","key":"1504_CR70","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/hec.3259","volume":"25","author":"H Al-Janabi","year":"2016","unstructured":"Al-Janabi H, Van Exel J, Brouwer W, Trotter C, Glennie L, Hannigan L, et al. Measuring health spillovers for economic evaluation: a case study in meningitis. Health Econ. 2016;25(12):1529\u201344.","journal-title":"Health Econ"},{"issue":"5","key":"1504_CR71","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/01.aud.0000233967.11072.24","volume":"27","author":"GR Barton","year":"2006","unstructured":"Barton GR, Stacey PC, Fortnum HM, Summerfield AQ. Hearing-impaired children in the United Kingdom, IV: cost-effectiveness of pediatric cochlear implantation. Ear Hear. 2006;27(5):575\u201388.","journal-title":"Ear Hear"},{"issue":"1","key":"1504_CR72","first-page":"43","volume":"154","author":"JE Bennett","year":"2000","unstructured":"Bennett JE, Sumner W 2nd, Downs SM, Jaffe DM. Parents\u2019 utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000;154(1):43\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"2","key":"1504_CR73","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1542\/peds.2004-0778","volume":"115","author":"CN Brouwer","year":"2005","unstructured":"Brouwer CN, Maill\u00e9 AR, Rovers MM, Veenhoven RH, Grobbee DE, Sanders EA, et al. Effect of pneumococcal vaccination on quality of life in children with recurrent acute otitis media: a randomized, controlled trial. Pediatrics. 2005;115(2):273\u20139.","journal-title":"Pediatrics"},{"issue":"1","key":"1504_CR74","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jpeds.2009.01.040","volume":"155","author":"AE Carroll","year":"2009","unstructured":"Carroll AE, Downs SM. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr. 2009;155(1):21\u20135 (5.e1-5).","journal-title":"J Pediatr"},{"issue":"7","key":"1504_CR75","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1001\/jama.284.7.850","volume":"284","author":"AK Cheng","year":"2000","unstructured":"Cheng AK, Rubin HR, Powe NR, Mellon NK, Francis HW, Niparko JK. Cost-utility analysis of the cochlear implant in children. JAMA. 2000;284(7):850\u20136.","journal-title":"JAMA"},{"issue":"1","key":"1504_CR76","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40801-016-0099-9","volume":"4","author":"B Crawford","year":"2017","unstructured":"Crawford B, Hashim SS, Prepageran N, See GB, Meier G, Wada K, et al. Impact of pediatric acute otitis media on child and parental quality of life and associated productivity loss in Malaysia: a prospective observational study. Drugs Real World Outcomes. 2017;4(1):21\u201331.","journal-title":"Drugs Real World Outcomes"},{"issue":"5 Suppl 1","key":"1504_CR77","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.jval.2011.05.007","volume":"14","author":"J Galante","year":"2011","unstructured":"Galante J, Augustovski F, Colantonio L, Bardach A, Caporale J, Marti SG, et al. Estimation and comparison of EQ-5D health states\u2019 utility weights for pneumococcal and human papillomavirus diseases in Argentina, Chile, and the United Kingdom. Value Health. 2011;14(5 Suppl 1):S60\u20134.","journal-title":"Value Health."},{"issue":"6","key":"1504_CR78","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","volume":"36","author":"MR Gold","year":"1998","unstructured":"Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36(6):778\u201392.","journal-title":"Med Care"},{"issue":"11","key":"1504_CR79","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/1477-7525-11-201","volume":"20","author":"CH Heidemann","year":"2013","unstructured":"Heidemann CH, Godballe C, Kjeldsen AD, Johansen EC, Faber CE, Lauridsen HH. The Otitis Media-6 questionnaire: psychometric properties with emphasis on factor structure and interpretability. Health Qual Life Outcomes. 2013;11:201.","journal-title":"Health Qual Life Outcomes"},{"key":"1504_CR80","unstructured":"Institute of Medicine Committee to Study Priorities for Vaccine D. The National Academies Collection: Reports funded by National Institutes of Health. In: Stratton KR, Durch JS, Lawrence RS, editors. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington (DC): National Academies Press (US). 2000"},{"issue":"2","key":"1504_CR81","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1651-2227.2003.tb00523.x","volume":"92","author":"I Koomen","year":"2003","unstructured":"Koomen I, Grobbee DE, Jennekens-Schinkel A, Roord JJ, van Furth AM. Parental perception of educational, behavioural and general health problems in school-age survivors of bacterial meningitis. Acta Paediatr. 2003;92(2):177\u201385.","journal-title":"Acta Paediatr"},{"issue":"5","key":"1504_CR82","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1542\/peds.93.5.697","volume":"93","author":"MS Kramer","year":"1994","unstructured":"Kramer MS, Etezadi-Amoli J, Ciampi A, Tange SM, Drummond KN, Mills EL, et al. Parents\u2019 versus physicians\u2019 values for clinical outcomes in young febrile children. Pediatrics. 1994;93(5):697\u2013702.","journal-title":"Pediatrics"},{"issue":"7","key":"1504_CR83","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/INF.0000000000000265","volume":"33","author":"T Kujala","year":"2014","unstructured":"Kujala T, Alho OP, Kristo A, Uhari M, Renko M, Pokka T, et al. Quality of life after surgery for recurrent otitis media in a randomized controlled trial. Pediatr Infect Dis J. 2014;33(7):715\u20139.","journal-title":"Pediatr Infect Dis J"},{"issue":"13","key":"1504_CR84","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1471-2431-13-122","volume":"13","author":"W Kulpeng","year":"2013","unstructured":"Kulpeng W, Sornsrivichai V, Chongsuvivatwong V, Rattanavipapong W, Leelahavarong P, Cairns J, et al. Variation of health-related quality of life assessed by caregivers and patients affected by severe childhood infections. BMC Pediatr. 2013;13(13):122.","journal-title":"BMC Pediatr"},{"issue":"3","key":"1504_CR85","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1651-2227.2008.01136.x","volume":"98","author":"R Legood","year":"2009","unstructured":"Legood R, Coen PG, Knox K, Viner RM, El Bashir H, Christie D, et al. Health related quality of life in survivors of pneumococcal meningitis. Acta Paediatr. 2009;98(3):543\u20137.","journal-title":"Acta Paediatr"},{"issue":"1","key":"1504_CR86","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0149-2918(96)80188-3","volume":"18","author":"PI Oh","year":"1996","unstructured":"Oh PI, Maerov P, Pritchard D, Knowles SR, Einarson TR, Shear NH. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin Ther. 1996;18(1):160\u201382.","journal-title":"Clin Ther"},{"issue":"8","key":"1504_CR87","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0895-4356(02)00448-1","volume":"55","author":"R Oostenbrink","year":"2002","unstructured":"Oostenbrink R, Ha AM, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol. 2002;55(8):791\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1504_CR88","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/0272989X08327398","volume":"29","author":"S Petrou","year":"2009","unstructured":"Petrou S, Kupek E. Estimating preference-based health utilities index mark 3 utility scores for childhood conditions in England and Scotland. Med Decis Making. 2009;29(3):291\u2013303.","journal-title":"Med Decis Making"},{"issue":"2","key":"1504_CR89","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1542\/peds.113.2.283","volume":"113","author":"LA Prosser","year":"2004","unstructured":"Prosser LA, Ray GT, O\u2019Brien M, Kleinman K, Santoli J, Lieu TA. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics. 2004;113(2):283\u201390.","journal-title":"Pediatrics"},{"key":"1504_CR90","unstructured":"Stouthard ME, Essink-Bot ML, Bonsel GJ, Barendregt JJ, Kramers PG, Van de Water HP, et al. Disability weights for diseases in the Netherlands. 1997."},{"key":"1504_CR91","first-page":"37","volume":"20","author":"GW Torrance","year":"1982","unstructured":"Torrance GW. Preferences for health states: a review of measurement methods. Mead Johnson Symp Perinat Dev Med. 1982;20:37\u201345.","journal-title":"Mead Johnson Symp Perinat Dev Med"},{"issue":"5","key":"1504_CR92","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/322587","volume":"33","author":"LJ Erickson","year":"2001","unstructured":"Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33(5):737\u20139.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1504_CR93","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1001\/archotol.125.11.1214","volume":"125","author":"AK Cheng","year":"1999","unstructured":"Cheng AK, Niparko JK. Cost-utility of the cochlear implant in adults: a meta-analysis. Arch Otolaryngol Head Neck Surg. 1999;125(11):1214\u20138.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"1","key":"1504_CR94","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1086\/313601","volume":"30","author":"P Vold Pepper","year":"2000","unstructured":"Vold Pepper P, Owens DK. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. Clin Infect Dis. 2000;30(1):157\u201364.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1504_CR95","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1542\/peds.2004-1283","volume":"114","author":"P Beutels","year":"2004","unstructured":"Beutels P, Viney RC. Comments on the Prosser et Al approach to value disease reduction in children. Pediatrics. 2004;114(5):1375 (author reply -6).","journal-title":"Pediatrics"},{"issue":"10","key":"1504_CR96","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1007\/s11136-023-03411-3","volume":"32","author":"M \u00c5str\u00f6m","year":"2023","unstructured":"\u00c5str\u00f6m M, Thet Lwin ZM, Teni FS, Burstr\u00f6m K, Berg J. Use of the visual analogue scale for health state valuation: a scoping review. Qual Life Res. 2023;32(10):2719\u201329.","journal-title":"Qual Life Res"},{"issue":"9","key":"1504_CR97","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2165\/11317060-000000000-00000","volume":"27","author":"DR Wright","year":"2009","unstructured":"Wright DR, Wittenberg E, Swan JS, Miksad RA, Prosser LA. Methods for measuring temporary health States for cost-utility analyses. Pharmacoeconomics. 2009;27(9):713\u201323.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1504_CR98","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1542\/peds.2004-1630","volume":"114","author":"LA Prosser","year":"2004","unstructured":"Prosser LA, Lieu TA. Comments on the Prosser et al approach to value disease reduction in children: in reply. Pediatrics. 2004;114(5):1375\u20136.","journal-title":"Pediatrics"},{"issue":"6","key":"1504_CR99","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s11136-010-9648-y","volume":"19","author":"N Wille","year":"2010","unstructured":"Wille N, Badia X, Bonsel G, Burstr\u00f6m K, Cavrini G, Devlin N, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010;19(6):875\u201386.","journal-title":"Qual Life Res"},{"issue":"Suppl 1","key":"1504_CR100","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40273-024-01350-6","volume":"42","author":"A van Heusden","year":"2024","unstructured":"van Heusden A, Rivero-Arias O, Herdman M, Hiscock H, Devlin N, Dalziel K. Psychometric performance comparison of the adapted versus original versions of the EQ-5D-Y-3L and -Y-5L in proxy respondents for 2- to 4-year-olds. Pharmacoeconomics. 2024;42(Suppl 1):129\u201345.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1504_CR101","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40273-019-00873-7","volume":"38","author":"D Rowen","year":"2020","unstructured":"Rowen D, Rivero-Arias O, Devlin N, Ratcliffe J. Review of valuation methods of preference-based measures of health for economic evaluation in child and adolescent populations: where are we now and where are we going? Pharmacoeconomics. 2020;38(4):325\u201340.","journal-title":"Pharmacoeconomics"},{"key":"1504_CR102","volume-title":"Measuring and valuing health for children: a review of the evidence: technology review","author":"CADTH Health Technology Review","year":"2024","unstructured":"CADTH Health Technology Review. Measuring and valuing health for children: a review of the evidence: technology review. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2024."},{"key":"1504_CR103","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.vhri.2019.01.003","volume":"18","author":"S Shahjouei","year":"2019","unstructured":"Shahjouei S, Vafaei Sadr A, Khorasani S, Nejat F, Habibi Z, Akbari SA. Utility measures in pediatric temporary health states: comparison of prone positioning valuation through 5 assessment tools. Value Health Reg Issues. 2019;18:97\u2013105.","journal-title":"Value Health Reg Issues."},{"issue":"8","key":"1504_CR104","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1477-7525-8-28","volume":"12","author":"GM Lee","year":"2010","unstructured":"Lee GM, Salomon JA, Gay C, Hammitt JK. Preferences for health outcomes associated with group A Streptococcal disease and vaccination. Health Qual Life Outcomes. 2010;12(8):28.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"1504_CR105","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1524-4733.2010.00711.x","volume":"13","author":"S Petrou","year":"2010","unstructured":"Petrou S, Dakin H, Abangma G, Benge S, Williamson I. Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value Health. 2010;13(5):543\u201351.","journal-title":"Value Health."},{"key":"1504_CR106","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2011.13228","volume":"141","author":"P Schuetz","year":"2011","unstructured":"Schuetz P, Albrich WC, Suter I, Hug BL, Christ-Crain M, Holler T, et al. Quality of care delivered by fee-for-service and DRG hospitals in Switzerland in patients with community-acquired pneumonia. Swiss Med Wkly. 2011;141: w13228.","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"1504_CR107","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12879-017-2302-3","volume":"17","author":"MJ Mangen","year":"2017","unstructured":"Mangen MJ, Huijts SM, Bonten MJ, de Wit GA. The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect Dis. 2017;17(1):208.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1504_CR108","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12955-018-0854-6","volume":"16","author":"LF Andrade","year":"2018","unstructured":"Andrade LF, Saba G, Ricard JD, Messika J, Gaillat J, Bonnin P, et al. Health related quality of life in patients with community-acquired pneumococcal pneumonia in France. Health Qual Life Outcomes. 2018;16(1):28.","journal-title":"Health Qual Life Outcomes"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01504-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01504-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01504-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:31:27Z","timestamp":1757179887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01504-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":108,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1504"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01504-0","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"6 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M.H., E.E., and S.M. are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who may own stock and\/or hold stock options in Merck & Co., Inc. D.R. is a consultant for Merck & Co., Inc and is a member of the EuroQol group. J.X. is an employee of XL Source, Inc., a consulting company that has provided paid consulting services to this research project. H.R., Y.S., S.L., and D.L. are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Merck & Co., Inc. M.S.K. is a consultant for Merck & Co., Inc. and Invivyd and provided paid consulting services to this research project.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"M.H., E.E., and S.M. contributed to the conceptualization of the study. All authors contributed to the study design and methodology. J.X., H.R., S.L., and D.L. conducted literature search and data extraction. M.H. and J.X. developed the initial summary of the results. All authors contributed to the interpretation of the findings, the development of the initial draft of the manuscript, and the revisions of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}